Latest Breaking News On - பிங் ஆமாம் - Page 1 : comparemela.com

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021. Jay Roberts, Chief Executive Officer of Vyant Bio, will discuss corporate, scientific, and operational updates in relation to the Company’s recent merger between the predecessor, Cancer Genetics, Inc., and StemoniX, Inc. Mr. Roberts will be joined on the call by Vyant Bio’s Chief Innovation Officer, Ping Yeh, and Chief Financial Officer, Andy LaFrence. Please also visit the Investors’ section of the Vyant Bio web site for

Andy lafrenceJenniferk zimmonsVyant bioJay robertsCompany nasdaqAccreditation of laboratory animal care internationalVyant bio or companyCancer genetics incStemonix incExchange commissionVyant bio incZimmons international communications incAssociation for assessmentChief executive officerCancer geneticsChief innovation officer